Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
- 21 May 2007
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 8 (6) , 500-512
- https://doi.org/10.1016/s1470-2045(07)70146-8
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and DocetaxelClinical Cancer Research, 2005
- Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trialLung Cancer, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Treatment of non-small-cell lung cancer: state of the art and development of new biologic agentsOncogene, 2003
- Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Prolonged gemcitabine infusion in advanced non–small cell lung carcinomaCancer, 2003
- Clinical Implications of Prostaglandin and Thromboxane A2FormationNew England Journal of Medicine, 1988
- Clinical Implications of Prostaglandin and Thromboxane A2FormationNew England Journal of Medicine, 1988